MRM2 and central nervous system cancer: In a glioma risk prediction formula proposed by Wang et al. in 2021, MRM2 and TRMT2B (tRNA methyltransferase 2 homolog B) are indicated as the primary predictors of the prognosis and clinicopathologic features for glioma patients26.